Kronos Bio Inc (NAS:KRON)
$ 0.94 0.02 (2.17%) Market Cap: 56.72 Mil Enterprise Value: -43.55 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 32/100

Kronos Bio Inc Phase 1/2 KB-0742 Data Update Call Transcript

Oct 13, 2023 / 08:30PM GMT
Release Date Price: $0.9925 (-13.70%)
Sarah Connors
Kronos Bio, Inc. - Vice President of Investor Relations & Corporate Communications

Thank you, operator, and good afternoon, everyone. I'm Sarah Connors, Vice President of Investor Relations and Corporate Communications at Kronos Bio. Earlier today, we issued a press release on Kronos Bio's positive preliminary data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study at AACR Triple Meeting. You may find this press release on our website, kronosbio.com in the Investors section.

Today, you will hear from Kronos Bio management, including Dr. Norbert Bischofberger, President and Chief Executive Officer; and Dr. Jorge DiMartino, Chief Medical Officer and Executive Vice President of Clinical Development. Norbert and Jorge will provide a brief overview of Kronos Bio, our science, and the KB-0742 program.

KB-0742 is Kronos Bio's internally discovered, highly selective, oral cyclin dependent kinase 9 inhibitor being developed to treat MYC-dependent solid tumors. We are very pleased to have trial investigator. Dr. Miguel Villalona, Medical Oncologist and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot